Evaluation of Primary Nonadherence to Oral Bisphosphonate Therapy

2013 ◽  
Vol 61 (11) ◽  
pp. 2046-2047 ◽  
Author(s):  
Keri N. Hogan ◽  
Jessica L. Milchak ◽  
Rachel M. F. Heilmann ◽  
Sarah J. Billups ◽  
Thomas Delate
Keyword(s):  
Bisphosphonate Therapy ◽  
Oral Bisphosphonate ◽  
Primary Nonadherence

scholarly journals A Clinical and Histological Study about the Socket Preservation in a Patient under Oral Bisphosphonates Treatment: A Case Report

Biology ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 262
Author(s):  
Antonello Falco ◽  
Francesco Bataccia ◽  
Lorenzo Vittorini Orgeas ◽  
Federico Perfetti ◽  
Mariangela Basile ◽  
...  
Keyword(s):  
Case Report ◽  
Histological Study ◽  
Healing Process ◽  
Signs And Symptoms ◽  
Bisphosphonate Therapy ◽  
Graft Material ◽  
Oral Bisphosphonates ◽  
Socket Preservation ◽  
Oral Bisphosphonate ◽  
Histological Data

The aim of the present study is to assess the clinical and histological healing of a post-extractive alveolus following the procedure for socket preservation, in a patient receiving oral bisphosphonates for more than 6 years. After the extraction, enzymatically-deantigenated horse bone granules and an equine pericardium membrane were used to preserve the tooth socket. The patient was placed on a monthly follow-up in order to monitor the healing process. A 3 mm trephine bur was used to drill the bone for implant site preparation and to collect the bone sample. No signs and symptoms related to osteonecrosis of the jaws were reported. Histological data showed that, after 5 months, the mean percentages of trabecular bone, bone marrow and residual bone graft were respectively 45.74 ± 0.09%, 48.09 ± 0.08%, and 6.16 ± 0.01%. The residual graft material appeared to be osteointegrated and none of the particles appeared to be encapsulated. The present case report supports the guidelines that assume that patients undergoing oral bisphosphonate therapy can be eligible for surgical therapy. More clinical studies with larger sample sizes are needed to support this clinical evidence.

scholarly journals Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy

2008 ◽  
Vol 26 (27) ◽  
pp. 4426-4434 ◽  
Author(s):  
Susan L. Greenspan ◽  
Joel B. Nelson ◽  
Donald L. Trump ◽  
Julie M. Wagner ◽  
Megan E. Miller ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Density ◽  
Bone Loss ◽  
Bone Turnover ◽  
Androgen Deprivation Therapy ◽  
Bisphosphonate Therapy ◽  
Androgen Deprivation ◽  
Mineral Density ◽  
Skeletal Health ◽  
Oral Bisphosphonate

Purpose Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures. Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT. Patients and Methods A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially received active therapy. Outcomes included bone mineral density and bone turnover markers. Results Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continue had additional bone density gains at the spine (mean, 2.3% ± 0.7) and hip (mean, 1.3% ± 0.5%; both P < .01); those randomly assigned to placebo in year 2 maintained density at the spine and hip but lost (mean, −1.9% ± 0.6%; P < .01) at the forearm. Patients randomly assigned to begin alendronate in year 2 experienced improvements in bone mass at the spine and hip, but experienced less of an increase compared with those who initiated alendronate at baseline. Men receiving alendronate for 2 years experienced a mean 6.7% (± 1.2%) increase at the spine and a 3.2% (± 1.5%) at the hip (both P < .05). Bone turnover remained suppressed. Conclusion Among men with nonmetastatic prostate cancer receiving ADT, once-weekly alendronate improves bone density and decreases turnover. A second year of alendronate provides additional skeletal benefit, whereas discontinuation results in bone loss and increased bone turnover. Delay in bisphosphonate therapy appears detrimental to bone health.

Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy

Bone ◽  
2013 ◽  
Vol 56 (2) ◽  
pp. 426-431 ◽  
Author(s):  
Paola Franceschetti ◽  
Marta Bondanelli ◽  
Gaetano Caruso ◽  
Maria Rosaria Ambrosio ◽  
Vincenzo Lorusso ◽  
...  
Keyword(s):  
Risk Factors ◽  
Femoral Fractures ◽  
Bisphosphonate Therapy ◽  
Atypical Femoral Fractures ◽  
Oral Bisphosphonate

ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY

2018 ◽  
Vol 24 (5) ◽  
pp. 405-410 ◽  
Author(s):  
Chiara Crotti ◽  
Nelson B. Watts ◽  
Maria De Santis ◽  
Angela Ceribelli ◽  
Gianluigi Fabbriciani ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Acute Phase ◽  
Protective Role ◽  
Bisphosphonate Therapy ◽  
Acid Infusion ◽  
Hydroxyvitamin D ◽  
Oral Bisphosphonate ◽  
25 Hydroxyvitamin D ◽  
Acute Phase Reactions

Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy

2016 ◽  
Vol 54 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Ramesh Srinivasan ◽  
David Rawlings ◽  
Claire L. Wood ◽  
Tim Cheetham ◽  
Aura Cecilia Jimenez Moreno ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Bisphosphonate Therapy ◽  
Oral Bisphosphonate
Sign in / Sign up

Export Citation Format

Share Document